Serologic and molecular typing of human T-lymphotropic virus among blood donors in Maputo City, Mozambique.

BACKGROUND: Screening for human T-lymphotropic virus-1/2 (HTLV-1/2) infection is not performed in blood banks in Mozambique. The aim was to determine the prevalence of HTLV-1/2 among blood donors of the Maputo Central Hospital Blood Bank and measure the coinfection rate of HTLV-1/2 with human immunodeficiency virus (HIV), hepatitis B virus (HBV), and syphilis. STUDY DESIGN AND METHODS: A total of 2019 consecutive blood donors were screened for HTLV-1/2 antibodies, HIV-1/2 antibodies, hepatitis B surface antigen (HBsAg), and rapid plasma reagin (RPR) for syphilis. Specimens reactive on a first HTLV-1/2 enzyme immunoassay (EIA) were retested using a second EIA. Specimens that were dually reactive on both EIAs were further tested using Western blot (WB) and real-time polymerase chain reaction (PCR). RESULTS: All 18 dually reactive specimens (0.89%; 95% confidence interval, 0.48%-1.30%) were positive for the presence of HTLV-1 by WB and real-time PCR. HTLV-2 was not detected. The prevalences of anti-HIV, HBsAg, and reactivity in the RPR test were 5.72, 6.01, and 0.98 percent, respectively. There was no significant association between HTLV-1 infection and demographic variables (age and sex) or serologic markers (HIV, HBsAg, and RPR). For the 17 HTLV-1-positive donors for whom serologic data for HIV, HBsAg, and syphilis RPR were available, 2 showed coinfection with HIV and 1 with HBV. CONCLUSION: Compared to other infectious agents, HTLV-1 is present at relatively low levels among blood donors in Mozambique. Cost and logistics will present as major challenges for introducing HTLV-1/2 screening in blood banks. In blood banks in Southern Africa where EIA testing is possible, a sequential algorithm of two EIAs may be a cost-efficient option for HTLV-1/2 screening.

Retrospective investigation of IgM antibodies against Zika virus in serum from febrile patients in Mozambique, 2009-2015.

OBJECTIVE: Zika virus (ZIKV) has emerged as an important health problem worldwide. The aim of this study was to investigate the occurrence, geographical distribution and trend of immunoglobulin M (IgM) antibodies against ZIKV between 2009 and 2015 in Mozambique. RESULTS: The median age of participants was 3 years [interquartile range (IQR): 1.0-6.0 years)] and 56.5% (480/850) of them were male. Of the 850 samples, 42 (4.9%) were positive for IgM antibodies against ZIKV. Positive samples were found in 9 provinces of the country. Frequency of IgM antibodies against ZIKV was slightly higher in patients aged 5-9 years old, and in the north region of the country.

Retrospective investigation of antibodies against chikungunya virus (CHIKV) in serum from febrile patients in Mozambique, 2009-2015: Implications for its prevention and control.

INTRODUCTION: Longitudinal data and trends about chikungunya virus (CHIKV) are critical for its control, however in Mozambique very few studies were conducted over 5 decades, between 1957 and 2013. In this study, we retrospectively investigated the occurrence, geographical distribution and trend of anti-CHIKV antibodies between 2009 and 2015 in Mozambique using serum samples from febrile patients. METHODS: A total of 895 serum samples collected from febrile patients for measles and rubella surveillance between 2009 and 2015 in 127 districts of Mozambique were retrospectively tested for IgM and IgG antibodies against CHIKV using a commercially available ELISA. RESULTS: The median age of patients was 2 years (IQR: 1-5 years) and 44.2% (395/895) of them were female. We found that 54 (6.0%) of samples were positive for anti-IgM chikungunya, and 160 (17.9%) were positive for anti-CHIKV IgG. Antibodies against CHIKV (IgM and IgG) were identified in serum throughout 2009 to 2015. While frequency of IgG antibodies was significantly higher in 2015 as compared to other years, frequency of IgM antibodies was homogeneous between 2009 and 2015. Antibodies against CHIKV were reported in all provinces and in 84 (66.1%) of the districts studied. Frequency of IgM and IgG antibodies was not significantly similar between age groups. CONCLUSION: This is the largest and longest serological screening of antibodies against CHIKV in febrile patients in Mozambique and findings from this study suggest that Mozambicans from all over the country have been silently exposed to CHIKV for several years.

Seroepidemiology of Rubella in Mozambique, 2006-2014: Implications for Rubella Immunization in Settings With High Fertility Rates.

BACKGROUND: Rubella and congenital rubella syndrome are highly underreported and neglected in most sub-Saharan countries and vaccination has not yet been incorporated into their national immunization schedules. In this study, we investigated the frequency of immunoglobulin M antibodies against rubella and examined correlations with fertility rates during the period from 2006 to 2014 in Mozambique. METHODS: We conducted a retrospective analysis of data collected through the routine case-based surveillance system for measles in Mozambique. RESULTS: A total of 7312 serum samples from suspected cases of measles were tested between 2006 and 2014. The median age was 4 years (interquartile range: 1-8 years). Of these, 1331 (18.2%) were positive for immunoglobulin M anti-rubella. The highest frequency of rubella was observed within the 5-9-year-old age group (32.6%). The frequency in the age groups <1 years old, 1-4, 10-14, 15-19, 20-29 and ≥30 were 4.5%, 13.1%, 28.7%,18.7%, 5.2% and 5.1%, respectively. CONCLUSION: Our data show that rubella is frequent among women of childbearing age in Mozambique. Considering that early pregnancy is common in Mozambique, this suggests that, in settings such as ours, the introduction of routine rubella vaccination in children should be accompanied by repeated vaccination campaigns targeting older children and adolescents.

Caracterização fenotípica de linfócitos T em crianças co-infectadas pelos vírus de imunodeficiência humana (HIV) e linfotrópico T humano tipo-1 / Phenotypic characterization of T-lymphocytes in children co-infected with human immunodeficiency virus (HIV) and human T-lymphotropic type-1 (HTLV-1)

O Vírus da Imunodificiência Humana tipo-1 (HIV) constitui uma das doenças infecciosas mais graves do mundo e particularmente em África onde mais de 2/3 de casos de todo o mundo foram reportados. Este cenário agrava-se na medida em que co-infecções possam surgir, tornando o sistema imune mais débil. O Vírus Linfotrópico da Células T Humanas (HTLV-1), tem sido implicado como frequente co-patogénese em regiões onde o HIV e HTLV são frequentes. A Influência do HTLV-1 na progressão da doença por HIV, está intimamente relaccionada, não apenas pelos eventos moleculares, mas também pelos seus poderes de induzirem activação celular. Contudo, os mecanismos pelo qual a activação crónica induzida pelo HTLV-1 pode potencialmente afectar a progressão para SIDA, em crianças, não está descrito. Neste estudo, analizamos o estado de activação de células T CD4 e T CD8 em crianças moçambicanas cronicamente infectadas por HIV-1, e estando em tratamento anti-retroviral (TARV). Para tal, analisamos as células apartir do sangue total dos pacientes co-infectados, mono-infectados (HIV) e controles não infectados por vírus (sadios). As células foram então marcadas com anticorpos específicos para as moléculas: CD4, CD8, CD25, CD45RA, CD45RO, CD38 e analisados por citometria de fluxo. Nossos resultados mostraram que nas crianças co-infectadas verifica-se uma expressão mais elevada do marcador CD25 e CD38, apesar de não se mostrarem estatisticamente significativos e um aumento no marcador CD45RO nos mesmo pacientes quando comparados com os mono-infectados e sadios. Concluindo, embora indivíduos co-infectados por HIV/HTLV- 1 apresentem contagens de células T CD4 elevados ou normais, estas células estão funcionalmente alteradas, apresentando níveis de activação celular elevados. (AU)

Caracterização fenotípica de linfócitos T em crianças co-infectadas pelos vírus de imunodeficiência humana (HIV) e linfotrópico T humano tipo-1 (HTLV-1)

O Vírus da Imunodificiência Humana tipo-1 (HIV) constitui uma das doenças infecciosas mais graves do mundo e particularmente em África onde mais de 2/3 de casos de todo o mundo foram reportados. Este cenário agrava-se na medida em que co-infecções possam surgir, tornando o sistema imune mais débil. O Vírus Linfotrópico da Células T Humanas (HTLV-1), tem sido implicado como frequente co-patogénese em regiões onde o HIV e HTLV são frequentes. A Influência do HTLV-1 na progressão da doença por HIV, está intimamente relaccionada, não apenas pelos eventos moleculares, mas também pelos seus poderes de induzirem activação celular. Contudo, os mecanismos pelo qual a activação crónica induzida pelo HTLV-1 pode potencialmente afectar a progressão para SIDA, em crianças, não está descrito. Neste estudo, analizamos o estado de activação de células T CD4 e T CD8 em crianças moçambicanas cronicamente infectadas por HIV-1, e estando em tratamento anti-retroviral (TARV). Para tal, analisamos as células apartir do sangue total dos pacientes co-infectados, mono-infectados (HIV) e controles não infectados por vírus (sadios). As células foram então marcadas com anticorpos específicos para as moléculas: CD4, CD8, CD25, CD45RA, CD45RO, CD38 e analisados por citometria de fluxo. Nossos resultados mostraram que nas crianças co-infectadas verifica-se uma expressão mais elevada do marcador CD25 e CD38, apesar de não se mostrarem estatisticamente significativos e um aumento no marcador CD45RO nos mesmo pacientes quando comparados com os mono-infectados e sadios. Concluindo, embora indivíduos co-infectados por HIV/HTLV- 1 apresentem contagens de células T CD4 elevados ou normais, estas células estão funcionalmente alteradas, apresentando níveis de activação celular elevados